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Abstract   
The recently analyzed genome of Naegleria gruberi, a free-living amoeboflagellate of the Heterolobosea clade, 
revealed a remarkably complex ancestral eukaryote with a rich repertoire of cytoskeletal-, motility- and 
signaling-genes. This protist, which diverged from other eukaryotic lineages over a billion years ago, possesses 
the ability for both amoeboid and flagellar motility. In a phylogenomic comparison of two free living 
eukaryotes with large proteomic datasets of three metastatic tumour entities (malignant melanoma, breast- and 
prostate-carcinoma), we find common proteins with potential importance for cell motility and cancer cell 
metastasis. To identify the underlying signaling modules, we constructed for each tumour type a 
protein-protein interaction network including these common proteins. The connectivity within this interactome 
revealed specific interactions and pathways which constitute prospective points of intervention for novel 
anti-metastatic tumour therapies. 
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1 Introduction 
Naegleria gruberi is a heterotrophic protist living primarily in its amoeba form in both freshwater and wet 
soils around the globe (De Jonckheere, 2002). Naegleria gruberi is best known for its remarkably fast 
differentiation from amoebae to flagellates with two anterior 9+2 flagella (Fulton, 1993). A transformation, 
which includes the construction of a complete new cytoplasmic microtubule cytoskeleton (Fulton, 1993).   
In addition, this amoeboflagellate can further exist as a resting cyst, which ultimately will produce the 
amoebae form (Fulton, 1993) and it posesses several key features that distinguish eukaryotes from prokaryotes 
including a complete actin and microtubule cytoskeleton and an extensive transcriptional machinery (Fulton 
and Walsh, 1980). 
The genomes of several other free-living protists have been sequenced (e.g., Dictyostelium (Eichinger and 
Noegel, 2005), Thalassiosira (Armbrust et al., 2004), Tetrahymena (Eisen et al., 2006), Paramecium (Aury et 
al., 2006), Chlamydomonas (Merchant et al., 2007), however the discovery of the Naegleria gruberi genome 
as a distant clade, allows for substantially broader phylogenomic comparisons of free-living eukaryotes than 
possible before (Fritz-Laylin et al., 2010). Network Biology, 2012, 2(2):45-56 
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Micromonas,  a member of the picophytoplankton group, is a free-living eukaryote found throughout 
marine ecosystems - from polar waters to the tropics (Worden, 2006). The Micromonas strain RCC299 (or 
NOUM17) (also known as Micromonas pusilla RCC299 or Micromonas sp. RC299) was isolated in 1998 in 
the Equatorial Pacific and its complete genome was sequenced 11 years later (Worden et al., 2009). Important 
in the context of this study is, that Micromonas RCC299 owes its motility to one single flagellum.   
Flagellar motility exists in all major eukaryotic groups (including the Heterolobosea clade of Naegleria 
gruberi) and therefore can be considered as an ancestral feature (Cavalier-Smith, 2002). Likewise, actin-based 
amoeboid locomotion is found in many diverse eukaryotic lineages and this form of motility also originated 
early in eukaryotic evolution, perhaps even being present in an eukaryotic ancestor (Fritz-Laylin et al., 2010; 
Cavalier-Smith, 2002; Fulton, 1970). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
         
Fig. 1 (A) Schematic view of the substraction aproach for the identification of amoeboid motility genes in cancer. For three 
different cancer types (breast carcinoma, prostate tumour and malignant melanoma) common genes with Naegleria gruberi were 
identified and substracted were genes present in Micromonas RCC299. Abreviations used are AM = amoeboid motility and FM = 
Flagellar motility. Naegleria gruberi is capable of both AM and FM whereas Micromonas only for FM. Our aproach selects for 
genes important for AM found in the different tumour types. (B) Variation of Coverage and Ident parameters and the distribution 
of matches between Naegelria gruberi and malignant melanoma. Different combinations of parameters for coverage, identities 
and gaps were tested in order to recognize a comfortable tipping point which may minimize false positives and false negatives. 
Subsequently, a requirement for 30% coverage, 25% identities and 10% gaps was used in our analyses as parameters for matches. 
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The amoeboid-like crawling of cells is a highly regulated cellular process which plays crucial roles for 
migrating cells during development as well as for metastasizing human tumour cells. This amoeboid 
movement is connected to the actin cytoskeleton dynamics and can be broken down into three essential steps 
(Fig. 1): protrusion of the leading edge, adhesion to the substrate, and retraction of the cell body (Mitchison 
and Cramer, 1996). Protrusion involves localized actin polymerization at the leading edge membrane, which 
ultimately leads to the extension of a lamellipod, a broad sheet-like structure. As the lamellipod advances, 
adhesions create molecular grips to the substrate. Retraction is the process wherein the adhesions are broken 
and the cell body is pulled forward. Protrusion is the best understood of these processes (Pollard and Borisy, 
2003).  
It is noteworthy to mention that amoeboid motility can exist without actin, an example for this exception is 
found in the nematode sperm where the cytoskeleton is based on the 14-kD major sperm protein, MSP, rather 
than on actin (Stewart et al., 1998). 
A better understanding of the molecular basis of cell motility is central for the identification of crucial 
mechanisms important for metastatic behaviour of tumour cells. Without question, invasion, migration and 
metastatic behaviour of cancer cells depends heavily on cell shape changes and cell motility.   
The fact that metastasis formation and the arising secondary tumours are responsible for more than 90% of 
all cancer deaths further stresses this importance (Jemal et al., 2007). In a complex process, primary tumour 
cells invade neighbouring tissues, intravasate the systemic circulation, transfer through the vasculature and the 
lymphatics, arrest in distant capillaries and lymphatic vessels, then extravasate into the perivascular tissue, and 
ultimately proliferate from micrometastases into macroscopic secondary tumours (Fidler, 2003; Marques et al., 
2009). 
Tumour progression involves a multitude of regulatory genes and signaling modules, of which many are 
still elusive (Ibrahim et al., 2011; Tacutu et al. 2011). Important during these processes are cell shape and 
surface changes, the interactions between tumour cells and their microenvironment including their 
neighbouring cells and of special importance is the motility of the malignant tumour cells (Marques et al., 
2009). 
Cancer cells that crawl trough a 3D matrix can be morphologically distinguished by two modes of invasion: 
one that appears as a mesenchymal cell movement that relies on proteolytic degradation of the surrounding 
matrix and another that adopts a rounded, more amoeboid mode of motility that frequently is accompanied by 
cell blebbing (Wolf et al., 2003; Sahai, 2005) showed that cancer cells invading through 3D collagen under 
conditions in which matrix degradation is blocked efficiently use an amoeboid mode of invasion with the 
formation of bleblike constriction rings. Consistent with this, some cancer cells preferentially use the 
bleb-associated amoeboid mode of invasion to bypass the requirement for extracellular matrix proteolysis or 
simply to switch modes of motility as an escape mechanism (Sahai and Marshall, 2003; Friedl, 2004).   
Furthermore, experimental induction of PM blebs in noninvasive cells promotes their ability to invade into 
3D matrices (Gadea et al., 2007; Tournaviti, 2007). One mode of cellular regulation occurs directly at the level 
of Rho, where activation of Rho causes PM blebbing and overexpression of RhoC induces a primitive 
amoeboid-like highly invasive phenotype characterized by the formation of dynamic membrane protrusions 
and blebs (Sander et al., 1999; Gadea et al., 2007). 
Although the role of amoeboid motility in cancer invasion and metastasis formation has been recognized, 
not much is known about the molecular mechanisms important for cell crawling (amoeboid movement) and 
bleb formation. The goal of this study is to identify the molecular modules and pathways important for 
amoeboid motility in human tumour cells (a schematic overview of our approach is shown in Fig.1 A).   
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2 Material and Methods 
2.1 Data collection and processing 
Proteomic comparisons were done using BLAST (Altschul et al., 1997). To interpret the results, a parser 
application was developed using AutoIt v3 (ver. 3.3.6.1, http://www.autoitscript.com/) which extracts and 
reprocesses outputs from any of NCBI’s BLAST web interface, BLAST+ (ver. 2.2.24) and NetBLAST (ver. 
2.2.24) into tab-delimited text files which can be imported and manipulated using a variety of statistical 
packages, such as Microsoft Excel. Unlike software packages developed with the same purpose in mind (e.g. 
Batch Blast Extractor (Pirooznia et al., 2008), Noblast, Jamblast (Lagnel et al., 2009), our script allowed 
side-by-side comparisons of multiple BLAST outputs of different organisms/proteomes against the same 
central proteome of interest. While the script was designed to extract all BLAST output data, only a vital 
subset (query length, identities % and gaps %) is carried forward into the output file in order to minimize 
processing load and clutter. In addition to these variables, a new value, “Coverage %” was calculated based on 
the relative sizes of the query and target sequences in order to allow a better interpretation of the results. 
Threshold values for Identities, Gaps and Coverage were determined and the highest scoring (E-score) was 
processed. 
2.2 Species comparison and proteome sources 
The proteomic data for prostate cancer was derived from five different patients with metastatic prostate 
carcinoma (Khan et al., 2010). For malignant melanoma a list of over 4000 proteins based on the transgenic 
mouse tumour model, TG3, was recently described (Zanivan et al., 2008). The  melanoma list of mouse 
proteins was BLASTed against the UniProt human protein database to generate the equivalent human proteins 
(no additional restrictions were used). Two studies describing the proteomic signatures of metastatic breast 
carcinoma were combined and used here for comparison (Johann et al., 2009; Wang et al., 2010). All of these 
different proteomic sources were used for our cross-species comparison to the proteomes of Naegleria gruberi 
(Fritz-Laylin et al., 2010) and Micromonas RCC299 (Worden et al., 2009). 
2.3 Constructing and visualizing the human interactome and the three cancer networks 
The HPRD (8
th release) list of human binary protein-protein interactions in tab delimited format was obtained 
from the HPRD website (http://www.hprd.org/). This list was loaded into the Cytoscape software (ver 2.6.3, 
http://www.cytoscape.org/) to visualize the human interactome network. The three lists of proteins (generated 
individually for each tumour type e.g. proteins found in the breast carcinoma proteome and in Naegleria 
gruberi but absent in Micromonas RCC299) were generated as described above. The Uniprot accession 
numbers and Entrez IDs of these lists were converted into the HPRD ID list format by using the converter at 
the Biomedical Information Research Center (BIRC) of the Japanese National Institute of Industrial Sciences 
and Technology (AIST) (http://biodb.jp/ids). After the conversion, the HPRD datasets were used to construct 
cancer networks on 3 different levels (zero, 1
st and second degree networks). The three different zero degree 
networks (the network including only genes from the respective lists) are shown in Fig. 2. Only the direct 
interactions between the listed genes were included in this network. The next level cancer networks included 
the interactions of the respective cancer AM genes with their 1
st neighbours, but excluded 
neighbour-neighbour interactions. The third network was set to include the cancer nodes as well as their 1
st and 
2
nd neighbours. The edges in this network represent the interactions between the cancer genes themselves, 
between them and their 1
st or 2
nd neighbours and between 1
st and 2
nd neighbours, but not the interactions 
among 2
nd neighbours . Due to the large size of the higher level networks and their similarity to each other and 
the general interactome, further analysis was restricted to the level of the 2
rd neighbour and below. 
Supplementary material shows the connectivity of all constructed networks, and of the entire interactome 
(Statistics section). 
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3 Results and Discussion 
3.1 Phylogenomic comparison of Naegleria gruberi and Micromonas RCC299 
We developed a parser application, which extracts and reprocesses outputs from any BLAST web interface 
(see Supplementary material tutorial). Our script allowed side-by-side comparisons of multiple BLAST 
outputs of different organisms, and we used this to compare the genomes of two distinct protists and to further 
perform a phylogenomic substraction analysis.   
Initially, we selected genes which were absent in Micromonas RCC299 and present in Naegleria gruberi. 
The former a monoflagellate, only able to move through its single flagellum and the latter an amoeboflagellate 
with the ability for both types of locomotion (amoeboid motility (AM) as well as flagellar motility (FM)). In 
this first step, we anticipated to enrich for amoeboid-motility-associated genes.   
Obviously, any phylogenetic analysis generated in this manner, will exclude genes that are used both for 
motility and other processes e.g., alpha-tubulin, which is used in flagella but also mitotic spindles (Fritz-Laylin 
et al., 2010) and further actin, Arp2/3 (which nucleates actin filaments), or other general actin cytoskeletal 
components, as these genes are found across eukaryotes regardless of their capacity for amoeboid locomotion 
(Fritz-Laylin et al., 2010). Nonetheless, some of these form the basis for locomotion, through their 
involvement in the dynamic cytoskeletal reorganization underlying amoeboid motility. Additionally, it is 
expectable that our two way phylogenomic comparison will have many false positives (genes not involved in 
amoeboid motility), Considering these aspects, we have incorporated two additional means for filtering in this 
study, which are desccribed and discussed below.   
The proteomes utilized, retrieved from the National Center for Biotechnology Information website in July, 
2010, were comprised of 20280 proteins and 31581 proteins for each of Micromonas RCC299 and Naegleria 
gruberi, respectively. 
3.2 Comparing different human tumour entities to the gene set enriched for amoeboid motility 
Subsequently, we use the set of genes found present in Naegleria gruberi but absent in Micromonas RCC299, 
to compare them directly to the “proteomic“ profiles of three different tumour entities. The proteomic data for 
prostate cancer was derived from five different patients with metastatic prostate carcinoma. The experimental 
strategy coupled isobaric tags for relative and absolute quantitation with multidimensional liquid phase peptide 
fractionation followed by tandem mass spectrometry. Over 1000 proteins were quantified across the specimens 
(Khan et al., 2010). 
For proteomic profiling of malignant melanoma, the transgenic mouse tumour model, TG3 was employed. 
These mutant mice carry skin melanomas and under defined experimental conditions, a total of 100 μg of solid 
tumour lysate yielded a melanoma proteome of 4443 identified proteins (Zanivan et al., 2008). 
For generating the proteomic signatures of metastatic breast carcinoma, human lymph node containing 
breast carcinoma metastasis of six specimens (~ 50,000 cell each) were collected by Laser Capture 
Microdissection and analysed by biological mass spectrometry. 367 proteins were identified in this approach 
(Johann et al., 2009). This proteome was further supplemented by data acquired from the biological 
spectrometric analysis of MCF-7 circulating tumor cells (Wang et al., 2010). 
Out of the 4437 malignant melanoma proteins we find here 340 present in Naegleria gruberi but absent in 
Micromonas RCC299, likewise out of 1031 prostate proteins investigated 105 were found and of the 1050 
breast carcinoma proteins tested 93 were found present in Naegleria gruberi but absent in Micromonas 
RCC299 (Supplementary material Statistics section). Found common among all three tumor entities were 29 
proteins (Table 1) (28 of these 29 proteins had HPRD IDs with the two exceptions: ACAT1 and LMAN2, 
which therefore do not appear in the common network). 
 
49Network Biology, 2012, 2(2):45-56 
  I A E E S                                                                                     www.iaees.org 
 
Fig. 2 Interactions linked to amoeboid motility (AM) of human cancer types. Shown are the cancer networks  for breast 
carcinoma (A), for malignant melanoma (B) and for prostate cancer (C). Shown are the 0 degree networks of the three tumour 
types. Indicated are self loops and in green are identified proteins linked to AM without direct interactions to other AM proteins. 
Highest connectivity is indicated in red. 
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Fig. 3 General networks based on the sets of AM linked proteins identified for the different cancer entities. Shown are the cancer 
networks for breast carcinoma (A), for malignant melanoma (B) and for prostate cancer (C). Shown are the 1 degree networks of 
the three tumour types including their first neighbours from the general interactome. 
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Fig. 4 Interaction and pathways identified in breast carcinoma, malignant melanoma and prostate cancer .Shown are examples of 
interactions identified in breast carcinoma (A), for malignant melanoma (B) and for prostate cancer (C). Identical interactions 
were found for breast and prostate cancer. 
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Fig. 5 Common identified proteins and their interactions. Shown are the 29 genes and their interactions identified in all three 
tumour types and in Naegleria gruberi but not found in Micromonas RCC299. 
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Table 1 Twenty nine proteins of three tumor entities 
Accession Gene  name    Synonyms Approved  name 
Q13085  ACACA  ACC1  acetyl-CoA carboxylase alpha 
Q96FG8 ACAT1  THIL  acetyl-CoA acetyltransferase 1 
Q96BG6  ACTN4  FSGS1  actinin, alpha 4 
Q59FV6 ACTR3  ARP3  ARP3  actin-related protein 3 homolog 
O43681  ASNA1    ARSA-I, GET3, TRC40  arsA arsenite transporter, ATP-binding, homolog 1 (bacterial) 
P52907  CAPZA1     capping protein (actin filament) muscle Z-line, alpha 1 
P47756  CAPZB     capping protein (actin filament) muscle Z-line, beta 
Q9P1I0  CPNE3     copine III 
Q7Z4W1  DCXR  DCR, KIDCR, SDR20C1,    dicarbonyl/L-xylulose reductase 
Q53XC0  EIF2S1 EIF-2alpha,  EIF2A eukaryotic  translation initiation factor 2, subunit 1 alpha 
P38117 ETFB  FP585  electron-transfer-flavoprotein, beta polypeptide 
P00367  GLUD1  GDH  glutamate dehydrogenase 1 
Q5TZX1 GNAI3  87U6 
guanine nucleotide binding protein (G protein), alpha inhibiting 
activity polypeptide 3 
Q71UM7 GNB1     
guanine nucleotide binding protein (G protein), beta 
polypeptide 1 
P06396 GSN  DKFZp313L0718  gelsolin 
P55084 HADHB    MTPB,  MSTP029 
hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA 
thiolase/enoyl-CoA hydratase (trifunctional protein), beta 
subunit 
Q99714 HSD17B10 
ABAD, CAMR, ERAB, 
MHBD, MRPP2, SDR5C1, 
HADH2 
hydroxysteroid (17-beta) dehydrogenase 10 
Q96GW1  HSP90B1  GP96, GRP94  heat shock protein 90kDa beta (Grp94), member 1 
O75874  IDH1  PICD  isocitrate dehydrogenase 1 (NADP+), soluble 
P48735  IDH2     isocitrate dehydrogenase 2 (NADP+), mitochondrial 
Q12907  LMAN2    GP36B, VIP36  lectin, mannose-binding 2 
Q99497  PARK7  DJ-1, DJ1  parkinson protein 7 
P00558  PGK1  PGKA, MIG10  phosphoglycerate kinase 1 
P14618 PKM2 
OIP3 PK2 PK3 PKM, 
THBP1 
pyruvate kinase, muscle 
P60900 PSMA6 
IOTA, MGC2333, p27K, 
PROS27 
proteasome (prosome, macropain) subunit, alpha type, 6 
Q15185  PTGES3  cPGES, p23, TEBP  prostaglandin E synthase 3 
Q00325 SLC25A3  PHC 
solute carrier family 25 (mitochondrial carrier; phosphate 
carrier), member 3 
Q8WVW9 SRP9      signal  recognition particle 9kDa 
O43592  XPOT  XPO3  exportin, tRNA (nuclear export receptor for tRNAs) 
29 genes were identified which were found in all three tumour types and in Naegleria gruberi but were absent from 
Micromonas RCC299. Gene name according to Human Gene Nomenclature (HGNC). 
 
 
3.3 Creating protein-protein interaction networks for the identified gene sets   
Since this comparative analysis will include some false positive genes not linked to amoeboid-motility, we 
added the involvement in the amoeboid-motility protein-protein interaction network as another criteria. 
Through this novel aproach we identify not single genes, but whole signaling modules and pathways and we 
anticipate that this method is likely to exclude most of the false negatives and positives of the regular species 
comparisons. We created three individual networks for prostate cancer, breast carcinoma and malignant 
melanoma, respectively and one network consisting of the thirty genes common among all three tumour 
entities and present in Naegleria gruberi but absent from Micromonas RCC299 (Fig. 5). 
54Network Biology, 2012, 2(2):45-56 
  I A E E S                                                                                     www.iaees.org 
Acknowledgement 
We would like to thank Professor Stephan Verleysdonk for his initial help with the experimental design and 
input. 
 
References 
Altschul SF, Madden TL, Schaffer AA, et al. 1997. Gapped BLAST and PSI-BLAST: a new generation of 
protein database search programs. Nucleic Acids Research, 25: 3389-3402 
Armbrust EV, Berges JA, Bowler C, et al. 2004. The genome of the diatom Thalassiosira pseudonana: 
ecology, evolution, and metabolism. Science, 306: 79-86 
Aury JM, Jaillon O, Duret L, et al. 2006. Global trends of whole-genome duplications revealed by the ciliate 
Paramecium tetraurelia. Nature, 444: 171-178 
Cavalier-Smith T. 2002. The phagotrophic origin of eukaryotes and phylogenetic classification of Protozoa. 
International Journal of Systematic and Evolutionary Microbiology, 52: 297-354 
De Jonckheere JF. 2002. A century of research on the amoeboflagellate genus Naegleria. Acta Protozoologica, 
41: 34 
Eichinger L, Noegel AA. 2005. Comparative genomics of Dictyostelium discoideum and Entamoeba 
histolytica. Current Opinion in Microbiology, 8: 606-611 
Eisen JA, Coyne RS, Wu M, et al. 2006. Macronuclear genome sequence of the ciliate Tetrahymena 
thermophila, a model eukaryote. PLoS Biology, 4: e286 
Fidler IJ. 2003. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nature Reviews 
Cancer, 3: 453-458 
Friedl P. 2004. Prespecification and plasticity: shifting mechanisms of cell migration. Current Opinion in Cell 
Biology, 16: 14-23 
Fritz-Laylin LK, Prochnik SE, Ginger ML, et al. 2010. The genome of Naegleria gruberi illuminates early 
eukaryotic versatility. Cell, 140: 631-642 
Fulton C. 1970. Amebo-flagellates as research partners: The laboratory biology of Naegleria and Tetramitus. 
Methods in Cell Physiology, 4: 341-346 
Fulton C. 1993. Naegleria: A research partner for cell and developmental biology. Journal of Eukaryotic 
Microbiology, 40: 520-532 
Fulton C, Walsh C. 1980. Cell differentiation and flagellar elongation in Naegleria gruberi dependence on 
transcription and translation. Journal of Cell Biology, 85: 346-360 
Gadea G, de Toledo M, Anguille C, et al. 2007. Loss of p53 promotes RhoA-ROCK-dependent cell migration 
and invasion in 3D matrices. Journal of Cell Biology, 178: 23-30 
Ibrahim SS, Eldeeb MAR, Rady MAH, et al. 2011. The role of protein interaction domains in the human 
cancer network. Network Biology, 1(1): 59-71 
Jemal A, Siegel R, Ward E, et al. 2007. Cancer statistics, 2007. CA-A Cancer Journal for Clinicians, 57: 43-66 
Johann DJ, Rodriguez-Canales J, Mukherjee S, et al. 2009. Approaching solid tumor heterogeneity on a 
cellular basis by tissue proteomics using laser capture microdissection and biological mass spectrometry. 
Journal of Proteome Research, 8: 2310-2318 
Khan AP, Poisson LM, Bhat VB, et al. 2010. Quantitative proteomic profiling of prostate cancer reveals a role 
for miR-128 in prostate cancer. Molecular and Cellular Proteomics, 9: 298-312 
Lagnel J, Tsigenopoulos CS, Iliopoulos I. 2009. NOBLAST and JAMBLAST: new options for BLAST and a 
Java application manager for BLAST results. Bioinformatics, 25: 824-826 
Marques IJ, Weiss FU, Vlecken DH, et al. 2009. Metastatic behaviour of primary human tumours in a 
55Network Biology, 2012, 2(2):45-56 
  I A E E S                                                                                     www.iaees.org 
zebrafish xenotransplantation model. BMC Cancer, 9: 128 
Merchant SS, Prochnik SE, Vallon O, et al. 2007. The Chlamydomonas genome reveals the evolution of key 
animal and plant functions. Science, 318: 245-250 
Mitchison TJ, Cramer LP. 1996. Actin-based cell motility and cell locomotion. Cell, 84: 371-379 
Pirooznia M, Perkins EJ, Deng Y. 2008. Batch Blast Extractor: an automated blastx parser application. BMC 
Genomics, 9(Suppl 2): S10 
Pollard TD, Borisy GG. 2003. Cellular motility driven by assembly and disassembly of actin filaments. Cell, 
112: 453-465 
Sahai E. 2005. Mechanisms of cancer cell invasion. Current Opinion in Genetics and Development, 15: 87-96 
Sahai E, Marshall CJ. 2003. Differing modes of tumour cell invasion have distinct requirements for 
Rho/ROCK signalling and extracellular proteolysis. Nature Cell Biology, 5: 711-719 
Sander EE, ten Klooster JP, van Delft S, et al. 1999. Rac downregulates Rho activity: reciprocal balance 
between both GTPases determines cellular morphology and migratory behavior. Journal of Cell Biology, 
147: 1009-1022 
Stewart M, Roberts TM, Italiano JE Jr, et al. 1998. Amoeboid motility without actin: insights into the 
molecular mechanism of locomotion using the major sperm protein (MSP) of nematodes. Biological 
Bulletin, 194(3): 342-343; discussion 343-344 
Tacutu R, Budovsky A, Yanai H, et al. 2011.Immunoregulatory network and cancer-associated genes: 
molecular links and relevance to aging. Network Biology, 1(2): 112-120 
Tournaviti S, Hannemann S, Terjung S, et al. 2007. SH4-domain-induced plasma membrane dynamization 
promotes bleb-associated cell motility. Journal of Cell Science, 120: 3820-3829 
Wang N, Xu M, Wang P, et al. 2010. Development of mass spectrometry-based shotgun method for proteome 
analysis of 500 to 5000 cancer cells. Analytical Chemistry, 82: 2262-2271 
Wolf K, Mazo I, Leung H, et al. 2003. Compensation mechanism in tumor cell migration: 
mesenchymal-amoeboid transition after blocking of pericellular proteolysis. Journal of Cell Biology, 160: 
267-277 
Worden AZ. 2006. Picoeukaryote diversity in coastal waters of the Pacific Ocean. Aquatic Microbial Ecology, 
43: 165-175 
Worden AZ, Lee JH, Mock T, et al. 2009. Green evolution and dynamic adaptations revealed by genomes of 
the marine picoeukaryotes Micromonas. Science, 324: 268-272 
Zanivan S, Gnad F, Wickstrom SA, et al. 2008. Solid tumor proteome and phosphoproteome analysis by high 
resolution mass spectrometry. Journal of Proteome Research, 7: 5314-5326 
 
56